Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Target Validation, 2011
    TFEB and Its Associated MicroRNA-128 as Targets for Neuroprotection and Disease Intervention in Parkinson´s Disease

    Objective/Rationale:
    Recent studies indicate that degenerative changes seen in Parkinson´s disease (PD) may be linked to impairments in the cells´ ability to degrade toxic proteins, such as misfolded...

  • Therapeutics Development Initiative, 2011
    Novel Oral Treatment for Parkinson's Disease Based on Highly Specific Modulation of the Indirect Pathway

    Objective/Rationale:
    Envoy Therapeutics’ target discovery technology enables the identification of new drug targets that have very selective expression in brain circuits of therapeutic interest thereby...

  • Alpha-Synuclein Imaging, 2011
    Consortium to Develop an Alpha-synuclein Imaging Agent

    Objective/Rationale: 
    The ultimate goal of this project is develop a positron emission tomography (PET) radiotracer to image the distribution of alpha-synuclein in the brain. Alpha-synuclein imaging...

  • Research Grant, 2011
    Testing Effects of Improved Levodopa Delivery with Dexterity and Gait Objective Measures

    Objective/Rationale: 
    The objective of this project is to develop an extended-release capsule of levodopa/carbidopa (IPX066) that will result in constant blood levels of levodopa compared to current...

  • Repositioning Drugs for PD, 2011
    Duloxetine Hydrochloride as a Novel Neuroprotective Treatment for Parkinson's Disease

    Objective/Rationale: 
    In Parkinson’s disease (PD) dopaminergic neurons in the midbrain region substantia nigra pars compacta die. There is currently no treatment available that prevents this cell death...

  • Repositioning Drugs for PD, 2011
    Evaluation of a Specific DAT Inhibitor in Pre-clinical Models of Parkinson's Disease

    Objective/Rationale: 
    MLR-1017 is a psychostimulant drug used clinically for a variety of neuropsychiatric and other applications, but has never been tested in Parkinson’s disease (PD). Levodopa is a...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.